CHILDREN'S ADVIL-FLAVORED (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1996.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
Children's Advil is an ibuprofen suspension formulated and flavored for pediatric patients to manage pain and fever. It works by inhibiting cyclooxygenase enzymes, reducing prostaglandin production and inflammation. This oral suspension is a nonsteroidal anti-inflammatory drug (NSAID) approved since 1996.
Product lifecycle is in decline phase with moderate competitive pressure (30%), indicating reduced investment and team consolidation opportunities.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on CHILDREN'S ADVIL-FLAVORED at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCareer opportunities on Children's Advil are limited due to product maturity and approaching LOE with zero linked job openings currently available. Working on this product offers experience in defensive brand management and mature market strategy but limited upside or expansion potential.